StockData

KALA BIO, Inc. (KALA) stock

KALANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 19, 2026Score 5/30
$3.43−0.40 (-10.44%)

Close on Nov 17, 2026Market cap $66.34MP/E –Yield –

Kala Bio total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Kala Bio's total debt was $28.41M at Sep 30, 2025. For fiscal 2024 it was $30.44M, down 11.0% from the year before. The highest annual figure on record is $78.93M in fiscal 2021.

Annual total debt

PeriodPeriod endValueChange
FY2024Dec 31, 2024$30.44M-11.0%
FY2023Dec 31, 2023$34.19M-20.4%
FY2022Dec 31, 2022$42.94M-45.6%
FY2021Dec 31, 2021$78.93M+9.3%
FY2020Dec 31, 2020$72.24M+1.5%
FY2019Dec 31, 2019$71.18M+1.4%
FY2018Dec 31, 2018$70.23M+276.5%
FY2017Dec 31, 2017$18.65M+93.2%
FY2016Dec 31, 2016$9.65M–

Quarterly total debt

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2025Sep 30, 2025$28.41M-19.1%
Q2 FY2025Jun 30, 2025$28.30M-18.7%
Q1 FY2025Mar 31, 2025$30.62M-11.2%
Q4 FY2024Dec 31, 2024$30.44M-11.0%
Q3 FY2024Sep 30, 2024$35.14M+3.7%
Q2 FY2024Jun 30, 2024$34.82M+3.7%
Q1 FY2024Mar 31, 2024$34.50M+3.7%
Q4 FY2023Dec 31, 2023$34.19M-20.4%
Q3 FY2023Sep 30, 2023$33.88M-20.6%
Q2 FY2023Jun 30, 2023$33.57M-57.9%
Q1 FY2023Mar 31, 2023$33.27M-58.1%
Q4 FY2022Dec 31, 2022$42.94M-45.6%
Q3 FY2022Sep 30, 2022$42.64M-45.7%
Q2 FY2022Jun 30, 2022$79.80M+2.2%
Q1 FY2022Mar 31, 2022$79.36M+9.4%
Q4 FY2021Dec 31, 2021$78.93M+9.3%
Q3 FY2021Sep 30, 2021$78.49M+9.1%
Q2 FY2021Jun 30, 2021$78.06M+8.9%
Q1 FY2021Mar 31, 2021$72.52M+1.5%
Q4 FY2020Dec 31, 2020$72.24M+1.5%
Q3 FY2020Sep 30, 2020$71.97M+1.5%
Q2 FY2020Jun 30, 2020$71.70M+1.4%
Q1 FY2020Mar 31, 2020$71.44M+1.4%
Q4 FY2019Dec 31, 2019$71.18M+1.4%
Q3 FY2019Sep 30, 2019$70.94M+258.5%
Q2 FY2019Jun 30, 2019$70.69M+257.6%
Q1 FY2019Mar 31, 2019$70.46M+256.8%
Q4 FY2018Dec 31, 2018$70.23M+276.5%
Q3 FY2018Sep 30, 2018$19.79M+0.2%
Q2 FY2018Jun 30, 2018$19.77M+103.6%
Q1 FY2018Mar 31, 2018$19.75M+104.5%
Q4 FY2017Dec 31, 2017$18.65M–
Q3 FY2017Sep 30, 2017$19.74M–
Q2 FY2017Jun 30, 2017$9.71M–
Q4 FY2016Dec 31, 2016$9.65M–

More Kala Bio figures

See a number that looks wrong?